Navigation Links
Protein Sciences Prepared to Combat the Latest Potential Pandemic Flu Virus
Date:5/2/2013

MERIDEN, Conn., May 2, 2013 /PRNewswire/ -- Protein Sciences announced today that it had completed development of the vector required to manufacture a vaccine to protect against the new and deadly H7N9 Bird Flu and is prepared to commence manufacturing within a few days of receiving orders for the vaccine.

It has been possible to move quickly and safely to develop the H7N9 vaccine because we use modern, proprietary, recombinant technology that enables us to develop vaccines for potentially deadly viruses without the use of a live disease virus and, therefore, without any risk to personnel.

We could manufacture the vaccine in our Pearl River, NY facility that we leased from Pfizer in November 2012.  In just 100 days we have been able to renovate the facility, restore it to full operating condition for our technology and manufacture three lots of antigens for our seasonal influenza vaccine, Flublok® that was approved by the FDA in January 2013.  Significant help in the process has been obtained from the State of New York and Rockland County and from current and former Pfizer personnel who have been incredibly helpful and supportive.

Manon Cox , President and CEO of Protein Sciences said, "We are excited that we have been able to move so quickly on the H7N9 vaccine.  We have consistently been first to have vaccines for potential pandemics, including manufacturing the first pandemic vaccine in 1997-98 in response to the Hong Kong Bird Flu.  We are very grateful for support from the Centers for Disease Control and Prevention who provided us with a killed H7N9 virus that allowed us to start the process."  She added, "Our Pearl River manufacturing facility has sufficient capacity to allow us to manufacture more than twice the number of doses of pandemic influenza vaccine in a six month period than is required by our contract with the Biomedical Advanced Research and Development Authority (BARDA)."

About Us

Protein Sciences Corporation is a vaccine development and protein production company that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceu­ticals.  

On January 16, 2013, the U.S. FDA approved Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease, for use in adults 18-49 years old. 

Flublok and its sister vaccine, Panblok®, that is designed to protect against pandemic influenza, have been developed in partnership with BARDA through Contract No. HHS0100200900106C. 

Learn more at www.proteinsciences.com and www.flublok.com.


'/>"/>
SOURCE Protein Sciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
2. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
3. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
4. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
5. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
6. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
7. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
8. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
9. Ventana Medical Systems, Inc. develops first-ever fully automated dual-stain technique for miRNA and protein detection in cancer
10. ProteinSimple Charges Ahead with the Simple Western
11. Advantages of Pressure BioSciences PCT Platform Highlighted at a Recent International Scientific Conference Focused on the Role of Proteins in the Cause, Prevention, and Treatment of Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
(Date:4/19/2017)... /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces ... Investor Conference 2017 at the Sheraton Hotel in Toronto, ... Officer of the Company is scheduled to present on Tuesday, May ... and the Chairman of the Board, Tony Holler will ... For ...
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report ... score performance for the 2015-16 school year across Wisconsin’s public schools, charter schools, ... highlights important patterns in student test score performance, the report’s limited analyses fail ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... on contracted partners to help with process innovation in drug formulation and manufacturing. ... experience along with state-of-the-art analytical equipment in support of their development and manufacturing ...
(Date:4/25/2017)... ... 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine ... focus on preventative care with all my patients to alleviate possible future issues. I am ... to contact my office and my trained staff will assist you in any way possible.” ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... 24, 2017 , ... Michael Vick announced his retirement earlier this year from ... overall number one pick in the 2001 NFL Draft, to the Atlanta Falcons, made ... the most career rushing yards by a quarterback (6,109) and the most rushing yards ...
Breaking Medicine News(10 mins):